Page 444 - Binder2

• Edible biologics grown in plants that engage the
immune system differently.
• Oral delivery systems that trigger mucosal tolerance
rather than alarm.
• AI-optimized growth platforms that remove cold
chains and sterile fill-finish bottlenecks.
• Case studies where patients gained not just
symptom relief, but biological peace.

Those chapters told a story of possibility—of science that
no longer fights the immune system, but learns from it.

But science alone is not enough.

The Real Bottleneck Isn’t Technical—It’s Structural

As with every medical revolution, the greatest resistance
doesn’t come from biology. It comes from infrastructure:

• From regulatory frameworks built for molecules,
not platforms.
• From investment models that reward velocity, not
longevity.
• From clinical cultures that accept drug failure as
routine.
• From healthcare systems designed for procedures,
not prevention.

We now stand at an inflection point. The tools exist. The
science is here. What remains is to reshape the
ecosystem—the policies, mindsets, and incentives that
determine whether better biologics ever make it to the
people who need them most.

442